KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $2.0 million.

  • Novavax's Capital Expenditures rose 4701.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 7287.12%. This contributed to the annual value of $13.1 million for FY2024, which is 7571.74% down from last year.
  • Novavax's Capital Expenditures amounted to $2.0 million in Q3 2025, which was up 4701.17% from $247000.0 recorded in Q2 2025.
  • Over the past 5 years, Novavax's Capital Expenditures peaked at $24.6 million during Q3 2022, and registered a low of $247000.0 during Q2 2025.
  • Its 5-year average for Capital Expenditures is $11.3 million, with a median of $12.2 million in 2021.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1092480.0% in 2021, then crashed by 9244.41% in 2024.
  • Over the past 5 years, Novavax's Capital Expenditures (Quarter) stood at $13.4 million in 2021, then soared by 72.08% to $23.0 million in 2022, then plummeted by 61.61% to $8.8 million in 2023, then crashed by 78.14% to $1.9 million in 2024, then rose by 4.4% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $247000.0 for Q2 2025, and $1.2 million during Q1 2025.